• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Can Praxis Precision Medicines' (PRAX) Extended Cash Runway Offset Mounting Losses In Its CNS Pipeline Push?

    Simply Wall St·08/10/2026 09:26:31
    Listen to the news
    • Praxis Precision Medicines recently reported its second-quarter 2026 results, posting a net loss of US$83.72 million and basic loss per share from continuing operations of US$2.87, while six-month losses reached US$176.28 million with a basic loss per share of US$6.08.
    • Despite the larger losses, management highlighted continued progress on late-stage central nervous system drug candidates and reiterated that its cash resources are expected to fund operations into 2028, placing near-term attention on upcoming regulatory and clinical milestones rather than on revenue generation.
    • With this backdrop of higher losses but reaffirmed funding into 2028, we’ll examine how the updated cash runway reshapes Praxis’s investment narrative.

    The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.

    Praxis Precision Medicines Investment Narrative Recap

    To own Praxis today you have to believe its late stage CNS pipeline, especially vormatrigine and relutrigine, can convert clinical promise into approved products before the cash runway into 2028 is tested. The wider Q2 2026 loss does not appear to change the near term focus, with the most important catalyst still tied to upcoming FDA decisions and key epilepsy readouts, and the biggest current risk remaining clinical or regulatory setbacks that prolong losses and increase financing pressure.

    The June 29 FDA decision to extend the relutrigine NDA review by three months is the most directly relevant recent announcement, because it pushes out one of Praxis’s closest potential value inflection points. While the agency did not cite new safety or manufacturing issues, the delay modestly shifts timing around a core catalyst for the developmental epileptic encephalopathy franchise and keeps attention on how regulatory outcomes will intersect with the company’s stated cash runway.

    Yet investors should be aware that the risk of cost overruns and potential dilution across five major trials drawing on the same cash pool may...

    Read the full narrative on Praxis Precision Medicines (it's free!)

    Praxis Precision Medicines’ narrative projects $1.7 billion revenue and $761.6 million earnings by 2029. This requires revenue to grow from zero to $1.7 billion and a $1,100.7 million earnings increase from -$339.1 million today.

    Uncover how Praxis Precision Medicines' forecasts yield a $643.06 fair value, a 78% upside to its current price.

    Exploring Other Perspectives

    PRAX 1-Year Stock Price Chart
    PRAX 1-Year Stock Price Chart

    Some of the most optimistic analysts once modeled Praxis reaching about US$2.8 billion in revenue and US$1.2 billion in earnings by 2029, a far more aggressive outcome than consensus, and the larger losses plus cash runway story could prompt both that bullish view and more cautious opinions to evolve as you weigh how much trial execution and capital risk you are really comfortable with.

    Explore 4 other fair value estimates on Praxis Precision Medicines - why the stock might be worth less than half the current price!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Curious About Other Options?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.